This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations
1 Citations
Facts about Interferon gamma receptor 1.
Plays an important role in the IFN-gamma pathway that is required for the cellular response to infectious agents (PubMed:20015550). .
Human | |
---|---|
Gene Name: | IFNGR1 |
Uniprot: | P15260 |
Entrez: | 3459 |
Belongs to: |
---|
type II cytokine receptor family |
AVP, type 2; CD119 antigen; CD119; FLJ45734; IFN-gamma R1; IFN-gamma receptor 1; IFNgammaR1; IFN-gamma-R1; IFNGR; IFNGR1; IFN-gR1; immune interferon receptor 1; interferon gamma receptor 1; interferon-gamma receptor alpha chain; type 2
Mass (kDA):
54.405 kDA
Human | |
---|---|
Location: | 6q23.3 |
Sequence: | 6; NC_000006.12 (137197484..137220351, complement) |
Cell membrane; Single-pass type I membrane protein.
Boster Bio is the most appropriate place to look to find an antibody against the IFNGR1 marker. Boster produces high affinity primary antibodies that have been extensively referenced in the scientific community for over 25 years. The boster antibody line has earned high acclaim in the research community and has been validated for use in Western Blotting, Immunohistochemistry, and ELISA.
Boster bio antibody to the human IFN gamma receptor (IFNG a/b). It can detect IFN a/b by using the IFNGR1 marker. The antibody originates from a mouse and interacts with mouse, human and IFN-G from rats. It is useful for immunofluorescence and Western blotting.
The IFN response pathway is highly temperature-dependent, with lower temperatures suppressing IFN-a/b responses. Antibodies that block this pathway are extremely effective for the treatment of viral infections. Because the IFN response pathway genes are highly temperature-dependent, it is important to find a suitable antibody to block IFN-a/b. There are numerous antibodies that target this pathway on the market.
The IFN Gamma receptor is expressed on a variety of different cells throughout the body including T lymphocytes B cells and NK cells. The IFN beta receptor is for the soluble IFNg. It is expressed on nearly all types of cells , excluding mature erythocytes. IFN gamma is highly species-specific and this antibody is not cross-reactive with mouse IFN Gamma.
Boster Bio's antis-IFNG-g antibody utilizes the IFNGR1 marker to determine the IFN-G gamma receptor. They can detect IFN-G+ cells, which are protective against Rotaviruses. These immune cells protect against gastrointestinal bacterial infections by being able to recognize antigens of rotavirus.
Picokine(tm), ELISA kits are highly sensitive and specific in the detection of IFNGR1 from a broad range of samples. The Picokine technology significantly increases the specificity and sensitivity of capture antibodies, which results in the sensitivity of a picogram. Picokine(tm), ELISA kits can be used with a variety of kinds of samples and are available in both in sandwich and 96-well formats.
Each kit includes the 96-well plates that have been coated with an anti-human IGF1R antibody. The resulting immunoblot results are then interpreted by a professional. The results are released within 24 hours and are applicable to many species. The sensitivity range of the ELISA kit is 0.02 percent to 2000 ng/well.
The IFNGR1 marker is identified using ELISA kits developed by Boster Bio, a leading antibody manufacturer. Boster Bio produces highly specific and sensitive antibodies. Its PICOBAND(tm) ELISA kits are highly sensitive, reaching levels of sensitivity in the picogram. Boster Bio products are tested by testing against a panel of more than 250 tissues. They can also be used in Flow Cytometry and IHC as well as ELISA applications.
Boster Bio has created a siRNA Oligonucleotide that targets the IFNGR1 genes. The RNA is designed to target the IFNGR1 gene, which plays a critical role in the immune system. The RNA targets cells as well as molecules and can therefore be used as an aid to treatment in the clinic.
The IFN-g receptor plays a crucial role in the development of autoimmune skin diseases. This fully chemically modified RNA silences the ligand binding chain of the IFN-g receptor and modulates the IFN-g signaling. It is designed to deliver to all types of skin cells and is delivered using the RNA-based treatment agent docosanoic acid (DCA). The siRNA can sustain a reduction in IFNGR1 protein over a time period of one month in mice and is a demonstration of the safety and efficacy of this novel treatment for the skin conditions that are autoimmune.
This new RNA-based treatment has a wide distribution across all types of cells. DCA-siRNA Ifngr1 1641 exhibits rapid silencing effects at week one. The effect of silencing is constant over time, as shown by the results of treating melanocytes and fibroblasts as well as Hematopoietic cell lines.
The RNA for this RNA-based therapy was isolated using an anion-exchange column on GE Source 15Q media. The RNA was stored at 4°C overnight for future use. The IFNGR1 marker siRNA oligonucleotide was used to detect IFN-G in the vivo and in vitro. Utilizing this oligonucleotide IFN-G-receptor signal from human tumors can be identified in only three weeks.
PMID: 2971451 by Aguet M., et al. Molecular cloning and expression of the human interferon-gamma receptor.
PMID: 8443182 by Stueber D., et al. Alignment of disulfide bonds of the extracellular domain of the interferon gamma receptor and investigation of their role in biological activity.
*More publications can be found for each product on its corresponding product page